Abstract
The special protocol assessment introduced only six years ago by the US Food and Drug Administration (FDA) to facilitate clinical trials is gaining popularity. Randy Osborne finds out why.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
